Patent · US Active

Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response

US11723963B2 · kind B2 · utility

0Cited by

15References

8Claims

0Family size

Assignee

University of Pittsburgh—Of the Commonwealth System of Higher Education · US

Inventors

Hideho Okada · Mill Valley, US
Walter J. Storkus · Pittsburgh, US

Key dates

Filing date	Sep 16, 2019
Grant date	Aug 15, 2023
Priority date	—
Expiry date	Dec 5, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/572
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides a peptide derived from the interleukin-13 receptor α2, which serves as a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope. The invention can be used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use. In addition, the invention provides the use of a peptide derived from the Eph family of tyrosine kinase receptors which can be also used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.